119 related articles for article (PubMed ID: 7232824)
1. Bestatin treatment and the peripheral lymphocyte population in cancer patients.
Blomgren H; Strender LE; Edsmyr F
Recent Results Cancer Res; 1980; 75():133-8. PubMed ID: 7232824
[TBL] [Abstract][Full Text] [Related]
2. Changes of the blood lymphocyte population in cancer patients treated with bestatin, a new immunomodulator. A phase I study.
Blomgren H; Strender LE; Edsmyr F
Biomedicine; 1980 Dec; 32(4):178-85. PubMed ID: 7470579
[TBL] [Abstract][Full Text] [Related]
3. Restoration of E-rosette formation by bestatin in patients with bladder cancer.
Yokoyama H; Umeda T; Kobayashi K; Akaza H; Niijima T
J Cancer Res Clin Oncol; 1980; 98(2):195-201. PubMed ID: 7217183
[TBL] [Abstract][Full Text] [Related]
4. [Experimental and clinical studies of bestatin as an immunomodulator].
Miwa H; Oka T; Tsurumi T; Sakae Y; Orita K
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1019-24. PubMed ID: 7184437
[TBL] [Abstract][Full Text] [Related]
5. Screening of small molecular microbial products modulating immune responses and bestatin.
Umezawa H
Recent Results Cancer Res; 1980; 75():115-25. PubMed ID: 7232823
[TBL] [Abstract][Full Text] [Related]
6. Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients.
Blomgren H; Edsmyr F; von Stedingk LV; Wasserman J
Biomed Pharmacother; 1986; 40(2):50-4. PubMed ID: 3756312
[TBL] [Abstract][Full Text] [Related]
7. Bestatin treatment of human lymphocytes increases the frequency of sheep red blood cell-binding cells.
Blomgren H; Wasserman J
Cancer Lett; 1981 Feb; 11(4):303-8. PubMed ID: 7296523
[TBL] [Abstract][Full Text] [Related]
8. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
9. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
[TBL] [Abstract][Full Text] [Related]
10. Effects of bestatin on the host immunity in patients treated for urogenital cancer.
Ozono S; Iwai A; Babaya K; Hiramatsu T; Yoshida K; Yamada K; Hirao Y; Aoyama H; Ohara S; Okajima E
Acta Oncol; 1990; 29(6):813-6. PubMed ID: 2223155
[TBL] [Abstract][Full Text] [Related]
11. [The immunomodulating action of bestatin in the combined therapy of bladder cancer patients].
Neprina GS; Panteleeva ES; Vatin OE; Kariakin OB
Urol Nefrol (Mosk); 1994; (2):34-8. PubMed ID: 8017004
[TBL] [Abstract][Full Text] [Related]
12. [A new antitumor drug with immunomodulating activity, ubenimex (bestatin)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2385-91. PubMed ID: 3496857
[TBL] [Abstract][Full Text] [Related]
13. Effect of bestatin on syngeneic tumors in mice.
Abe F; Shibuya K; Uchida M; Takahashi K; Horinishi H; Matsuda A; Ishizuka M; Takeuchi T; Umezawa H
Gan; 1984 Jan; 75(1):89-94. PubMed ID: 6586596
[TBL] [Abstract][Full Text] [Related]
14. A review of clinical studies of bestatin.
Oka S
Recent Results Cancer Res; 1980; 75():126-32. PubMed ID: 7015425
[TBL] [Abstract][Full Text] [Related]
15. Increased sensitivity of IL2-dependent cultured T cells and enhancement of in vitro IL2 production by human lymphocytes treated with Bestatin.
Noma T; Klein B; Cupissol D; Yata J; Serrou B
Int J Immunopharmacol; 1984; 6(2):87-92. PubMed ID: 6429060
[TBL] [Abstract][Full Text] [Related]
16. Do tuftsin and bestatin constitute a biopharmacological immunoregulatory system?
Mathé G
Cancer Detect Prev Suppl; 1987; 1():445-55. PubMed ID: 3319151
[TBL] [Abstract][Full Text] [Related]
17. Bestatin therapy of patients with atopic dermatitis.
Thestrup-Pedersen K; Cramers M; Kongsholm H; Zachariae H
Acta Derm Venereol; 1983; 63(6):549-52. PubMed ID: 6198850
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory and therapeutic properties of bestatin in mice.
Talmadge JE; Lenz BF; Pennington R; Long C; Phillips H; Schneider M; Tribble H
Cancer Res; 1986 Sep; 46(9):4505-10. PubMed ID: 2942238
[TBL] [Abstract][Full Text] [Related]
19. [Clinical studies of bestatin on genitourinary cancer].
Ichikawa T; Hirokawa I; Ishihara Y
Jpn J Antibiot; 1985 Jan; 38(1):166-78. PubMed ID: 3989976
[TBL] [Abstract][Full Text] [Related]
20. Decrease in saturation density of mammalian carcinoma cell culture during exposure to bestatin, a clinically applicable agent.
Okuyama S; Mishina H
Tohoku J Exp Med; 1984 Mar; 142(3):349-50. PubMed ID: 6729813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
